Erratum: Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD (Journal of the American Medical Association (2013) 310, 9 (918-929) DOI: 10.1001/jama.2013.277064);Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: The UMPIRE randomized clinical trial

JAMA

Volumn 310, Issue 9, 2013, Pages 918-929

  Thom, Simon ^a   Poulter, Neil ^a   Field, Jane ^a   Patel, Anushka ^b   Prabhakaran, Dorairaj ^c   Stanton, Alice ^d   Grobbee, Diederick E ^e   Bots, Michiel L ^e   Reddy, K Srinath ^f   Cidambi, Raghu ^g   Bompoint, Severine ^b   Billot, Laurent ^b   Rodgers, Anthony ^b  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b GEORGE INSTITUTE FOR GLOBAL HEALTH   (Australia)

^c CENTRE FOR CHRONIC DISEASE CONTROL   (India)

^d ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^f PUBLIC HEALTH FOUNDATION OF INDIA   (India)

^g DR REDDY'S LABORATORIES LTD   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID PLUS ATENOLOL PLUS HYDROCHLOROTHIAZIDE PLUS LISINOPRIL; ACETYLSALICYLIC ACID PLUS ATENOLOL PLUS LISINOPRIL PLUS SIMVASTATIN; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; CARDIAC AGENT; CARDIOVASCULAR AGENT; CHOLESTEROL; CREATININE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; BODY WEIGHT; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DISEASE CONTROL; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT;

EID: 84883392138     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2013.279933     Document Type: Erratum

References (40)

1. Yusuf S, Islam S, Chow CK, et al Prospective Urban Rural Epidemiology Study Investigators. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet. 2011;378(9798):1231-1243.
2. Webster RJ, Heeley EL, Peiris DP, BayramC, Cass A, Patel AA. Gaps in cardiovascular disease risk management in Australian general practice. Med J Aust. 2009;191(6):324-329.
3. Yusuf S, Pais P, Afzal R, et al Indian Polycap Study. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet. 2009;373(9672):1341-1351.
4. Rodgers A, Patel A, Berwanger O, et al PILL Collaborative Group. An international randomised placebo-controlled trial of a 4-component combination pill ("polypill") in people with raised cardiovascular risk. PLoS One. 2011;6(5):e19857.
5. Malekzadeh F, Marshall T, Pourshams A, et al. A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy ("polypill") on cardiovascular risk factors. Int J Clin Pract. 2010;64(9):1220-1227.
6. Lonn E, Bosch J, Teo KK, Pais P, Xavier D, Yusuf S. The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions. Circulation. 2010;122(20):2078-2088.
7. Elley CR, Gupta AK,Webster R, et al. The efficacy and tolerability of "polypills": meta-analysis of randomised controlled trials. PLoS One. 2012;7(12):e52145.
8. World Health Organization. Secondary Prevention of Noncommunicable Disease in Low and Middle Income Countries Through Community-Based and Health Service Interventions. Geneva, Switzerland:World Health Organization; 2002.
9. Lafeber M, SpieringW, Singh K, Guggilla RK, Patel V,Webster R; SPACE Collaboration. The cardiovascular polypill in high-risk patients. Eur J Cardiovasc Prev Rehabil. 2012;19(6):1234-1242. 8
10. British Cardiac Society. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart. 2005;91(suppl 5):v1-v52.
11. Smith SC Jr, Allen J, Blair SN, et al American Heart Association/American College of Cardiology; National Heart, Lung, and Blood Institute. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006;113(19):2363-2372. (Pubitemid 43947981)
12. Wald NJ, LawMR. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003;326(7404):1419.
13. World Health Organization. The World Health Report 2002: Reducing Risks, Promoting Healthy Life. Geneva, Switzerland:World Health Organization; 2002.
14. Yusuf S. Two decades of progress in preventing vascular disease. Lancet. 2002;360(9326):2-3. (Pubitemid 34756482)
15. Thom S, Field J, Poulter N, et al. Use of a Multidrug Pill in Reducing Cardiovascular Events (UMPIRE): rationale and design of a randomised controlled trial of a cardiovascular preventive polypill-based strategy in India and Europe. Eur J Prev Cardiol. 2012.
16. Selak V, Elley CR, Crengle S, et al. Improving Adherence Using Combination Therapy (IMPACT): design and protocol of a randomised controlled trial in primary care. Contemp Clin Trials. 2011;32(6):909-915.
17. Liu HM, Patel A, Brown A, et al Kanyini GAP Study Team; Kanyini Vascular Collaboration. Rationale and design of the Kanyini guidelines adherence with the polypill (Kanyini-GAP) study: a randomised controlled trial of a polypill-based strategy amongst indigenous and non indigenous people at high cardiovascular risk. BMC Public Health. 2010;10:458.
18. New Zealand Guidelines Group. New Zealand Cardiovascular Guidelines Handbook: A Summary Resource for Primary Care Practitioners. Wellington: New Zealand Guidelines Group; 2005.
19. EuroQol Group. EuroQol - a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199-208.
20. Hulley SB. Designing Clinical Research. 3rd ed. Philadelphia, PA: LippincottWilliams &Wilkins; 2007.
21. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288(4):455-461. (Pubitemid 34787476)
22. Newby LK, LaPointe NM, Chen AY, et al. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation. 2006;113(2):203-212.
23. Choudhry NK, Avorn J, Glynn RJ, et al Post-Myocardial Infarction Free Rx Event and Economic Evaluation (MI FREEE) Trial. Full coverage for preventive medications aftermyocardial infarction. N Engl J Med. 2011;365(22):2088-2097.
24. World Health Organisation. Adherence to Long-term Therapies: Evidence for Action. Geneva: World Health Organization; 2003.
25. Collins R, MacMahon S. Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials. Lancet. 2001;357(9253):373- 380. (Pubitemid 32128549)
26. Baigent C, Blackwell L, Collins R, et al Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborativemeta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849-1860.
27. Baigent C, Keech A, Kearney PM, et al Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospectivemeta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet . 2005;366(9493):1267-1278.
28. Turnbull F; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362(9395):1527-1535.
29. Law MR, Morris JK,Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.
30. Law MR,Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003;326(7404):1423.
31. Grimm R, Malik M, Yunis C, Sutradhar S, Kursun A; TOGETHER Investigators. Simultaneous treatment to attain blood pressure and lipid goals and reduced CV risk burden using amlodipine/atorvastatin single-pill therapy in treated hypertensive participants in a randomized controlled trial. Vasc Health Risk Manag. 2010;6:261-271.
32. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010;55(2):399-407.
33. Neutel JM, Bestermann WH, Dyess EM, et al. The use of a single-pill calcium channel blocker/statin combination in the management of hypertension and dyslipidemia: a randomized, placebo-controlled, multicenter study. J Clin Hypertens (Greenwich). 2009;11(1):22-30.
34. Wald DS, Morris JK,Wald NJ. Randomized polypill crossover trial in people aged 50 and over. PLoS One. 2012;7(7):e41297.
35. Soliman EZ, Mendis S, Dissanayake WP, et al. A Polypill for primary prevention of cardiovascular disease: a feasibility study of theWorld Health Organization. Trials. 2011;12(1):3.
36. Wells S, Broad J, Jackson R. Estimated prevalence of cardiovascular disease and distribution of cardiovascular risk in New Zealanders: data for healthcare planners, funders, and providers. N Z Med J. 2006;119(1232):U1935.
37. High-Level Expert Group Report on Universal Health Coverage Initiative for India. Access to medicines (pp 117-138). November 2011. http://uhc-india. org. Accessed August 14, 2013.
38. Frieden TR, Berwick DM. The "Million Hearts" initiative-preventing heart attacks and strokes. N Engl J Med. 2011;365(13):e27.
39. World Health Organization. Health 2020: The European Policy for Health andWell-being. Geneva, Switzerland:World Health Organization; 2012.
40. Beaglehole R, Ebrahim S, Reddy S, Voûte J, Leeder S; Chronic Disease Action Group. Prevention of chronic diseases: a call to action. Lancet. 2007;370(9605):2152-2157.